177 related articles for article (PubMed ID: 22520838)
1. Effects of sequence changes in the HIV-1 gp41 fusion peptide on CCR5 inhibitor resistance.
Anastassopoulou CG; Ketas TJ; Sanders RW; Klasse PJ; Moore JP
Virology; 2012 Jul; 428(2):86-97. PubMed ID: 22520838
[TBL] [Abstract][Full Text] [Related]
2. Resistance of a human immunodeficiency virus type 1 isolate to a small molecule CCR5 inhibitor can involve sequence changes in both gp120 and gp41.
Anastassopoulou CG; Ketas TJ; Depetris RS; Thomas AM; Klasse PJ; Moore JP
Virology; 2011 Apr; 413(1):47-59. PubMed ID: 21356539
[TBL] [Abstract][Full Text] [Related]
3. Differential use of CCR5 by HIV-1 clinical isolates resistant to small-molecule CCR5 antagonists.
Henrich TJ; Lewine NR; Lee SH; Rao SS; Berro R; Gulick RM; Moore JP; Tsibris AM; Kuritzkes DR
Antimicrob Agents Chemother; 2012 Apr; 56(4):1931-5. PubMed ID: 22252820
[TBL] [Abstract][Full Text] [Related]
4. Structure-function analysis of human immunodeficiency virus type 1 gp120 amino acid mutations associated with resistance to the CCR5 coreceptor antagonist vicriviroc.
Ogert RA; Ba L; Hou Y; Buontempo C; Qiu P; Duca J; Murgolo N; Buontempo P; Ralston R; Howe JA
J Virol; 2009 Dec; 83(23):12151-63. PubMed ID: 19776131
[TBL] [Abstract][Full Text] [Related]
5. Multiple CCR5 conformations on the cell surface are used differentially by human immunodeficiency viruses resistant or sensitive to CCR5 inhibitors.
Berro R; Klasse PJ; Lascano D; Flegler A; Nagashima KA; Sanders RW; Sakmar TP; Hope TJ; Moore JP
J Virol; 2011 Aug; 85(16):8227-40. PubMed ID: 21680525
[TBL] [Abstract][Full Text] [Related]
6. Evolution of CCR5 antagonist resistance in an HIV-1 subtype C clinical isolate.
Henrich TJ; Tsibris AM; Lewine NR; Konstantinidis I; Leopold KE; Sagar M; Kuritzkes DR
J Acquir Immune Defic Syndr; 2010 Dec; 55(4):420-7. PubMed ID: 20856130
[TBL] [Abstract][Full Text] [Related]
7. HIV-1 clinical isolates resistant to CCR5 antagonists exhibit delayed entry kinetics that are corrected in the presence of drug.
Putcharoen O; Lee SH; Henrich TJ; Hu Z; Vanichanan J; Coakley E; Greaves W; Gulick RM; Kuritzkes DR; Tsibris AM
J Virol; 2012 Jan; 86(2):1119-28. PubMed ID: 22090117
[TBL] [Abstract][Full Text] [Related]
8. Resistance to CCR5 inhibitors caused by sequence changes in the fusion peptide of HIV-1 gp41.
Anastassopoulou CG; Ketas TJ; Klasse PJ; Moore JP
Proc Natl Acad Sci U S A; 2009 Mar; 106(13):5318-23. PubMed ID: 19289833
[TBL] [Abstract][Full Text] [Related]
9. A low-molecular-weight entry inhibitor of both CCR5- and CXCR4-tropic strains of human immunodeficiency virus type 1 targets a novel site on gp41.
Murray EJ; Leaman DP; Pawa N; Perkins H; Pickford C; Perros M; Zwick MB; Butler SL
J Virol; 2010 Jul; 84(14):7288-99. PubMed ID: 20427524
[TBL] [Abstract][Full Text] [Related]
10. In vivo emergence of vicriviroc resistance in a human immunodeficiency virus type 1 subtype C-infected subject.
Tsibris AM; Sagar M; Gulick RM; Su Z; Hughes M; Greaves W; Subramanian M; Flexner C; Giguel F; Leopold KE; Coakley E; Kuritzkes DR
J Virol; 2008 Aug; 82(16):8210-4. PubMed ID: 18495779
[TBL] [Abstract][Full Text] [Related]
11. Vicriviroc resistance decay and relative replicative fitness in HIV-1 clinical isolates under sequential drug selection pressures.
Tsibris AM; Hu Z; Paredes R; Leopold KE; Putcharoen O; Schure AL; Mazur N; Coakley E; Su Z; Gulick RM; Kuritzkes DR
J Virol; 2012 Jun; 86(12):6416-26. PubMed ID: 22491471
[TBL] [Abstract][Full Text] [Related]
12. V1 and V2 Domains of HIV Envelope Contribute to CCR5 Antagonist Resistance.
Wu E; Du Y; Gao X; Zhang J; Martin J; Mitreva M; Ratner L
J Virol; 2019 May; 93(9):. PubMed ID: 30787151
[TBL] [Abstract][Full Text] [Related]
13. Mapping resistance to the CCR5 co-receptor antagonist vicriviroc using heterologous chimeric HIV-1 envelope genes reveals key determinants in the C2-V5 domain of gp120.
Ogert RA; Wojcik L; Buontempo C; Ba L; Buontempo P; Ralston R; Strizki J; Howe JA
Virology; 2008 Apr; 373(2):387-99. PubMed ID: 18190945
[TBL] [Abstract][Full Text] [Related]
14. Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor.
Kuhmann SE; Pugach P; Kunstman KJ; Taylor J; Stanfield RL; Snyder A; Strizki JM; Riley J; Baroudy BM; Wilson IA; Korber BT; Wolinsky SM; Moore JP
J Virol; 2004 Mar; 78(6):2790-807. PubMed ID: 14990699
[TBL] [Abstract][Full Text] [Related]
15. Reversible and efficient activation of HIV-1 cell entry by a tyrosine-sulfated peptide dissects endocytic entry and inhibitor mechanisms.
Platt EJ; Gomes MM; Kabat D
J Virol; 2014 Apr; 88(8):4304-18. PubMed ID: 24478426
[TBL] [Abstract][Full Text] [Related]
16. Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics.
Reeves JD; Gallo SA; Ahmad N; Miamidian JL; Harvey PE; Sharron M; Pohlmann S; Sfakianos JN; Derdeyn CA; Blumenthal R; Hunter E; Doms RW
Proc Natl Acad Sci U S A; 2002 Dec; 99(25):16249-54. PubMed ID: 12444251
[TBL] [Abstract][Full Text] [Related]
17. Clinical resistance to vicriviroc through adaptive V3 loop mutations in HIV-1 subtype D gp120 that alter interactions with the N-terminus and ECL2 of CCR5.
Ogert RA; Hou Y; Ba L; Wojcik L; Qiu P; Murgolo N; Duca J; Dunkle LM; Ralston R; Howe JA
Virology; 2010 Apr; 400(1):145-55. PubMed ID: 20172579
[TBL] [Abstract][Full Text] [Related]
18. Two HIV-1 variants resistant to small molecule CCR5 inhibitors differ in how they use CCR5 for entry.
Berro R; Sanders RW; Lu M; Klasse PJ; Moore JP
PLoS Pathog; 2009 Aug; 5(8):e1000548. PubMed ID: 19680536
[TBL] [Abstract][Full Text] [Related]
19. HIV-1 predisposed to acquiring resistance to maraviroc (MVC) and other CCR5 antagonists in vitro has an inherent, low-level ability to utilize MVC-bound CCR5 for entry.
Roche M; Jakobsen MR; Ellett A; Salimiseyedabad H; Jubb B; Westby M; Lee B; Lewin SR; Churchill MJ; Gorry PR
Retrovirology; 2011 Nov; 8():89. PubMed ID: 22054077
[TBL] [Abstract][Full Text] [Related]
20. Mapping and characterization of vicriviroc resistance mutations from HIV-1 isolated from treatment-experienced subjects enrolled in a phase II study (VICTOR-E1).
McNicholas PM; Mann PA; Wojcik L; Qiu P; Lee E; McCarthy M; Shen J; Black TA; Strizki JM
J Acquir Immune Defic Syndr; 2011 Mar; 56(3):222-9. PubMed ID: 21209592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
